Ian Bouligny
Articles
-
5 days ago |
nature.com | Alex Bataller |Hannah Goulart |Ghayas C. Issa |Courtney DiNardo |Tapan M Kadia |Ian Bouligny | +12 more
AbstractAcute myeloid leukemia (AML) with KMT2A rearrangement (KMT2Ar) has poor outcomes. We analyzed 1,611 patients with AML and 4.3% demonstrated rearrangements in KMT2A. Signaling-related genes (NRAS 30%, KRAS 23% and FLT3-TKD 16%) were the most frequently mutated in patients with KMT2Ar AML.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →